Page 4 - Scientific Library

There is an increasing demand for new cholesterol-lowering therapies in addition to existing treatments (e.g. targeting statins). The pharmacological inhibition of PCSK9-mediated LDLR degradation

The Silicon Rhodamine-like (SiR) technology has significantly contributed to the recent development of DNA and cytoskeletal analysis by live cell imaging.

Extracellular adenosine 5'-triphosphate (ATP) is released by dying and damaged cells, and it acts on many immune

Protein Gene Product 9.5 (PGP 9.5) is an abundant cytoplasmic neuron and neuroendocrine-cell specific protein. Over the years, this deubiquitinating enzyme (a.k.a. Ubiquitin Carboxy-terminal Hydrolase

ADCC is a simple but important mechanism for the immune system to target diseased or infected cells. Antibodies bind to specific

Immunotherapy represents a field in Drug Discovery which is quickly developing and leading to significant progress in treatments of a number of diseases, especially cancer. The approach is based on inducing,

Today, I'd like to give you an overview about methods in actin research with validated R&D products and kits which will allow you to measure binding to actin and effects on the polymerisation dynamics

On your journey to Biomarker profiling, you will reach the point where you need to quantify the proteins of interest identified along the way (eg. validation of semi-quantitative

Stauprimide is known to prime Embryonic Stem Cells (ESC) by targeting the c-Myc-activating transcription factor NME2. Its mechanism of action is linked to the inhibition of the nuclear localization

In a recent paper, Horita H. et al. identified a set of novel Post-Translational Modifications (PTMs) of the protein Programmed Cell Death Ligand (PD-L1).

Use of validated antibodies is primordial for Breast Cancer research and related biomarker discovery. Here, we'll review the main biomarkers involved in this disease and introduce the

PD-1:PD:-L1 immune checkpoint pathway targeting immunotherapies have shown great potential for many cancer patients. Recently, The FDA has granted accelerated approval to the immunotherapy drug pembrolizumab